International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

Reporting Patterns and Compliance in Ocular Pharmacovigilance: Insights from Ophthalmologists

Swati Rai [1], Sabahat Hasan [2], Vishal Yadav [3]

1. Swati Rai (Assistant Professor, Department of Pharmacology, ASMC Sultanpur) orcid id 0009000384091009
2. Sabahat Hasan (Assistant Professor, Department of Pharmacology, ASMC Sultanpur) orcid id 0009000475282871
3. Vishal Yadav (Assistant Professor, RIO, Institute of Medical Sciences, Banaras Hindu University) id 0009000584920123
Corresponding Author: Vishal Yadav (Assistant Professor, RIO, Institute of Medical Sciences, Banaras Hindu University)
Address: A-37, nilgiri residential apartment, Jodhpur colony, BHU-221005

Date of Submission: 01-05-2025 Date of Acceptance: 10-05-2025

ABSTRACT

Background

Pharmacovigilance is crucial for ensuring drug safety, particularly in ophthalmology, where adverse drug reactions (ADRs) can significantly impact patient care. However, ocular ADRs are underreported, necessitating an understanding of ophthalmologists' awareness, practices, and barriers to ADR reporting.**Purpoose**To evaluate awareness, reporting patterns, and compliance with ADR reporting systems among ophthalmologists, and identify barriers and facilitators influencing their practices.**Methods**A cross-sectional study was conducted among ophthalmologists working in tertiary care and private settings. Data were collected using a structured questionnaire addressing demographic details, knowledge of pharmacovigilance, ADR reporting frequency and methods, and perceived obstacles to reporting. Descriptive statistics and chi-square tests were used for data analysis.**Results**Among participants, 72% were aware of pharmacovigilance, but only 38% actively reported ADRs. Commonly reported ocular ADRs included allergic conjunctivitis, steroid-induced glaucoma, and ocular surface toxicity from topical medications. Barriers to reporting included lack of time (42%), insufficient knowledge of reporting procedures (35%), and absence of institutional support (18%). However, 65% of respondents expressed willingness to report ADRs if provided with training and simplified tools. **Conclusion** A significant gap exists between awareness and active ADR reporting among ophthalmologists. Addressing barriers through training programs, user-friendly reporting systems, and institutional support can enhance compliance and strengthen pharmacovigilance in ophthalmology. Integrating pharmacovigilance training into medical education and promoting a culture of safety reporting are essential to improving drug safety surveillance in this specialized field.

Keywords: pharmacovigilance, adverse drug reactions, ophthalmology, awareness, barriers, reporting compliance.

I. INTRODUCTION

Ensuring drug safety is a cornerstone of modern healthcare, with pharmacovigilance playing a critical role in safeguarding patient well-being. Pharmacovigilance refers to the science and activities associated with detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) or any other drug-related problems (1). Its significance is evident across all medical disciplines, as ADRs can undermine treatment efficacy, increase healthcare costs, and, in severe cases, threaten patient lives. Despite its critical role, pharmacovigilance in specialized fields like ophthalmology remains relatively underexplored (2).

Adverse drug reactions associated with ocular therapies, though less commonly reported compared to systemic drugs, hold significant potential to impact patient outcomes (3). These reactions can range from mild, transient discomfort such as ocular irritation or dryness to severe, vision-threatening complications like glaucoma or retinal damage. This variability underscores the necessity for vigilant monitoring and reporting. In ophthalmology, ADRs frequently result from the use of topical medications such as anti-glaucoma drugs, corticosteroids, and anti-VEGF agents (3). The unique anatomy and physiology of the eye,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

combined with the specialized pharmacokinetics of ophthalmic drugs, present distinctive challenges in detecting and reporting ADRs (6). For instance, topical medications applied to the eye can have systemic effects despite their localized administration, such as cardiovascular side effects associated with beta-blockers used for glaucoma (9). Subtle or gradual-onset reactions may also be overlooked or misattributed to disease progression or external factors, further complicating pharmacovigilance efforts in this field (5).

Globally, underreporting of ADRs remains a persistent issue in healthcare, attributed to a combination of systemic, educational, and logistical barriers. In ophthalmology, these challenges are compounded by the specialized nature of the field. This study aims to address the gap in understanding the practices and challenges of ocular ADR reporting among ophthalmologists. It explores their awareness of pharmacovigilance principles, the frequency and methods of ADR reporting, and the barriers impeding effective reporting. The study also examines the facilitators that could enhance reporting practices and compliance with existing pharmacovigilance systems (12, 14).

Key obstacles identified include lack of time, insufficient knowledge of reporting systems, and limited institutional support (12, 14). Despite these challenges, a significant proportion of ophthalmologists express willingness to engage in ADR reporting if provided with targeted training programs and simplified tools (11). Such findings highlight the potential for targeted interventions to improve ADR reporting compliance. Integrating pharmacovigilance training into medical education, developing user-friendly reporting systems, and fostering institutional support can empower ophthalmologists to actively contribute to pharmacovigilance efforts (7). Furthermore, cultivating a culture of safety reporting within ophthalmic practice can enhance the early detection and management of ADRs, ultimately benefiting patient care (13).

In conclusion, pharmacovigilance in ophthalmology requires focused attention to address the unique challenges posed by ocular therapies. By bridging the gap in ADR reporting, this study emphasizes the importance of targeted interventions to strengthen pharmacovigilance in this specialized field (6). Improving ADR monitoring and reporting not only enhances the safety of ophthalmic treatments but also ensures better outcomes for patients, reinforcing the broader goal of safer healthcare practices (15).

II. MATERIALS AND METHODS

A cross-sectional descriptive study was undertaken to evaluate the awareness, practices, and barriers associated with adverse drug reaction (ADR) reporting among ophthalmologists. This study encompassed 120 ophthalmologists from tertiary care hospitals, private practices, and academic institutions across diverse geographic regions, ensuring a comprehensive representation of the ophthalmology community (4). By including participants from a variety of professional backgrounds, the study aimed to capture a holistic view of ADR reporting patterns across diverse clinical environments.

The research was structured around a validated semi-structured questionnaire designed to collect extensive data across several domains:

1. **Demographics and Professional Details**: Data captured included participants' age, gender, years of professional experience, type of practice (tertiary care, private, or academic), and subspecialty within ophthalmology. This allowed the study to explore how demographic factors influence pharmacovigilance awareness and reporting behaviors.
2. **Awareness of Pharmacovigilance and ADR Reporting Systems**: This section assessed the participants' understanding of pharmacovigilance concepts, familiarity with existing ADR reporting systems, and the sources from which they gained knowledge about these systems (1, 5).
3. **Types and Frequency of Reported Ocular ADRs**: Participants were asked to detail the specific ADRs they had encountered in their practice, the frequency of their reporting, and the preferred methods for submitting ADR reports (6, 9). This helped identify the most common ADRs in ophthalmology and variations in reporting practices.
4. **Barriers and Facilitators to ADR Reporting**: Respondents were prompted to identify the primary challenges hindering ADR reporting and to suggest factors or tools that could enhance their participation in pharmacovigilance activities (12, 14).

The questionnaire was pretested on a subset of ophthalmologists to ensure clarity, reliability, and relevance of the questions.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

Feedback from this pilot phase was incorporated to refine the instrument (13). Ethical compliance was meticulously maintained throughout the study. Ethical approval was secured from the institutional ethics committee, and informed consent was obtained from all participants prior to their involvement (4). The confidentiality of participants' responses was safeguarded, and data was anonymized before analysis.

The data collection process spanned three months, during which participants were approached in person or via email. The questionnaire was disseminated electronically for convenience, especially for practitioners located in remote or busy settings. Follow-up reminders were sent to ensure a high response rate. Efforts were made to ensure inclusivity by recruiting participants from both urban and rural settings to capture variations in practice and reporting behaviors.

Quantitative data analysis was performed using SPSS software version 26. Descriptive statistics were employed to summarize demographic characteristics, professional details, and patterns in ADR awareness and reporting. Inferential statistics, including chi-square tests, were utilized to identify associations between variables such as years of experience and levels of pharmacovigilance awareness or reporting activity. Statistical significance was set at a p-value of <0.05 (9, 11). Additional qualitative data from open-ended questions were analyzed to gain insights into personal experiences and perceptions regarding ADR reporting.

By employing a robust methodology and integrating ethical rigor, this study aimed to provide actionable insights into the current state of ADR reporting in ophthalmology. The findings are intended to inform targeted interventions for improving pharmacovigilance practices within this specialized field.

III. RESULTS

Of the 120 participants, 95 (79%) completed the questionnaire, yielding a high response rate. The demographic characteristics revealed a diverse group of ophthalmologists, with an average age of 42 years and a balanced representation of male and female participants.

Awareness and Knowledge

Seventy-two percent of respondents reported being aware of pharmacovigilance. Among these, younger practitioners with 10 or fewer years of experience demonstrated higher levels of awareness compared to their senior counterparts with 11 or more years of experience ($p < 0.05$). Sources of awareness included medical education (45%), professional workshops (30%), and self-directed learning (25%). This highlights the growing integration of pharmacovigilance principles into the education and training of newer ophthalmologists.

ADR Reporting Practices

Despite relatively high levels of awareness, only 38% of respondents had reported an ADR in the past year. This reveals a significant gap between awareness and practice, a trend often noted in pharmacovigilance studies across various medical disciplines. Among the ADRs reported, the most common included:

- Allergic conjunctivitis induced by anti-glaucoma medications.
- Steroid-induced glaucoma and cataract.
- Ocular surface toxicity caused by preservatives in topical medications.

Preferred reporting methods varied among respondents. Most ophthalmologists (60%) favored electronic reporting systems for their convenience and accessibility, while 30% opted for manual submission of forms, citing familiarity with traditional methods. Notably, ophthalmologists working in institutions equipped with pharmacovigilance centers demonstrated higher reporting rates ($p < 0.05$), indicating the impact of institutional support on reporting compliance.

Barriers to Reporting

Key barriers to ADR reporting identified in this study include:

1. **Time Constraints**: Forty-two percent of respondents cited lack of time as a significant impediment to ADR reporting. The demanding nature of ophthalmic practice, particularly in busy clinical and surgical settings, limits the time available for completing reporting procedures.
2. **Insufficient Knowledge**: Thirty-five percent of participants reported inadequate understanding of ADR reporting systems, emphasizing the need for targeted training programs. While awareness of pharmacovigilance concepts is widespread, operational knowledge of reporting processes remains limited.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

3. **Lack of Institutional Incentives**: Eighteen percent of respondents pointed to the absence of institutional encouragement or recognition as a deterrent. This reflects a broader systemic issue where ADR reporting is not adequately prioritized or incentivized within healthcare organizations.

Facilitators and Motivators

Despite the identified barriers, the study revealed several factors that could enhance ADR reporting among ophthalmologists:

1. **Training Programs**: Sixty-five percent of respondents expressed willingness to engage in ADR reporting if provided with training programs focused on pharmacovigilance and ADR reporting procedures. Workshops, continuing medical education (CME) sessions, and hands-on training could bridge the knowledge gap and improve compliance.
2. **Simplified Reporting Tools**: The development of user-friendly reporting tools, such as mobile applications and online portals, emerged as a key facilitator. These tools could streamline the reporting process, making it quicker and more accessible for busy practitioners.
3. **Institutional Support**: Policies that recognize and encourage ADR reporting, such as awards for active reporters or integration of pharmacovigilance activities into quality assurance measures, were highlighted as potential motivators. Dedicated pharmacovigilance units within institutions could also provide the necessary infrastructure and support to facilitate reporting.

Comparative Insights

The findings align with global trends in pharmacovigilance, where underreporting of ADRs remains a universal challenge. However, the unique anatomical and pharmacological considerations of ophthalmology necessitate a tailored approach to ADR monitoring. For instance, the localized administration of ophthalmic drugs often leads to ADRs that are subtle, transient, or mistakenly attributed to underlying conditions. This complexity underscores the need for heightened vigilance and specialized training in ophthalmic pharmacovigilance.

Demographic Analysis

Younger ophthalmologists displayed a higher propensity to report ADRs, which may reflect the increasing emphasis on pharmacovigilance in contemporary medical education. Conversely, senior practitioners with greater clinical experience but limited formal training in pharmacovigilance exhibited lower reporting rates, highlighting the importance of lifelong learning and periodic sensitization programs.

Outcome Evaluation

The study underscores the critical role of targeted interventions in bridging the gap between awareness and practice. Training, technological innovations, and institutional incentives emerged as key strategies to improve ADR reporting rates among ophthalmologists. The willingness of a significant proportion of participants to engage in ADR reporting if provided with the necessary support is a promising finding that highlights the potential for systemic improvements in pharmacovigilance practices.

By analyzing the attitudes, practices, and barriers to ADR reporting, this study provides actionable insights into improving drug safety surveillance in ophthalmology. The findings can inform policy initiatives and guide the development of targeted interventions to strengthen pharmacovigilance systems within this specialized field. Further research is needed to evaluate the long-term impact of such interventions and to explore their applicability in other medical disciplines.

IV. DISCUSSION

The study reveals critical insights into the gaps and challenges in adverse drug reaction (ADR) reporting among ophthalmologists, a specialty where pharmacovigilance remains underutilized (3, 6). Although a majority of participants demonstrated awareness of pharmacovigilance principles, the low rate of actual ADR reporting highlights systemic barriers within clinical practice (4, 12).

Awareness vs. Practice

While awareness of pharmacovigilance among ophthalmologists is commendable, it does not necessarily translate into active reporting. This finding is consistent with previous research in other medical specialties, where underreporting remains a significant challenge despite widespread awareness (5, 9). This discrepancy underscores the importance of identifying and addressing barriers to reporting, which in this study included lack of

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

time, inadequate knowledge of reporting systems, and limited institutional support (12, 14).

Barriers to ADR Reporting

The most frequently cited obstacle was lack of time, reflecting the demanding nature of ophthalmology practice, particularly in busy clinical and surgical settings (12). Insufficient knowledge of reporting procedures also emerged as a significant barrier, suggesting that while ophthalmologists are familiar with the concept of pharmacovigilance, they may not be adequately trained in its operational aspects (5). Furthermore, the absence of institutional incentives or recognition for reporting ADRs discourages active participation (14). Institutions that fail to emphasize the importance of pharmacovigilance risk perpetuating a culture of neglect toward drug safety monitoring (6, 13).

Facilitators and Potential Interventions

Despite these barriers, the willingness of a majority of participants to engage in ADR reporting if provided with training and simplified tools is encouraging (11). This finding highlights the potential of targeted interventions to bridge the gap between awareness and practice (4). Simplified reporting tools, such as mobile apps or web-based platforms, can significantly reduce the time and effort required to report ADRs (11). These tools should be intuitive, accessible, and integrated with electronic medical record systems to facilitate seamless reporting (10).

Training programs are another essential component of improving ADR reporting practices (8). Regular workshops, continuing medical education (CME) sessions, and hands-on training can enhance the understanding of pharmacovigilance and equip ophthalmologists with the skills needed to identify and report ADRs effectively (5, 7). Importantly, these programs should be tailored to address the unique challenges of ophthalmic practice, such as the subtle or delayed presentation of certain ocular ADRs (3, 6).

Institutional Role

The role of institutions in fostering a culture of pharmacovigilance cannot be overstated (13). Institutions with established pharmacovigilance units and clear reporting protocols are more likely to encourage active participation (6, 14). Recognizing and rewarding ophthalmologists who contribute to ADR reporting can further incentivize compliance (12). Policies that integrate pharmacovigilance into routine clinical workflows, such as mandating ADR reporting as part of quality assurance measures, can ensure sustained engagement (8).

Comparative Insights and Broader Implications

The findings of this study align with global trends in pharmacovigilance, where underreporting is a universal challenge (5, 12). However, the unique anatomical and pharmacological considerations of ophthalmology necessitate a tailored approach to ADR monitoring (15). For instance, the localized administration of ophthalmic drugs often leads to ADRs that are subtle, transient, or mistakenly attributed to underlying conditions (3, 6). This complexity underscores the need for heightened vigilance and specialized training in ophthalmic pharmacovigilance (7, 9).

The broader implications of improving ADR reporting extend beyond ophthalmology (6, 13). A robust pharmacovigilance system ensures early detection of safety signals, leading to timely regulatory actions and improved patient safety (1, 4). It also fosters a culture of accountability and continuous learning among healthcare professionals, ultimately enhancing the quality of care (11, 14).

V. CONCLUSION

Pharmacovigilance in ophthalmology requires focused attention to overcome unique challenges in detecting and reporting ocular ADRs. While awareness of pharmacovigilance is relatively high among ophthalmologists, practical barriers hinder consistent reporting practices. Targeted interventions, including training, simplified reporting tools, and institutional support, are essential to bridge the gap between awareness and practice.

By fostering a culture of vigilance and accountability, ophthalmologists can contribute significantly to enhancing the safety of ocular drug therapies. These efforts not only benefit individual patients but also strengthen the broader healthcare system, ensuring that pharmacovigilance remains a cornerstone of modern medical practice.

To fully harness the potential of pharmacovigilance in ophthalmology, a long-term, sustained effort is essential. This effort must involve collaboration between healthcare professionals, institutions, policymakers, and regulatory authorities. The integration of pharmacovigilance into daily clinical practice

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 107-113 www.ijprajournal.com ISSN: 2456-4494

demands a collective commitment to prioritizing patient safety above all else.

Furthermore, as technology advances, leveraging digital platforms to streamline ADR reporting processes will be a game-changer. Automated systems integrated with electronic medical records can enhance the accuracy and ease of reporting while reducing the burden on healthcare providers. Regular audits and feedback mechanisms can also ensure that reporting systems remain efficient and relevant to the evolving needs of ophthalmic practice.

Lastly, the role of education cannot be overstated. By embedding pharmacovigilance training within medical and allied health curricula, future practitioners can be equipped with the knowledge and skills required to address ADRs effectively. This approach not only prepares them for their roles as clinicians but also fosters a culture of continuous learning and safety vigilance.

In conclusion, strengthening pharmacovigilance in ophthalmology is not merely an academic exercise; it is a clinical imperative. By addressing the current gaps and implementing strategic solutions, we can pave the way for a safer, more reliable therapeutic landscape for patients with ocular conditions. The success of these efforts will ultimately depend on the collective resolve of all stakeholders to prioritize pharmacovigilance as an integral component of comprehensive patient care.

REFERENCES

[1]. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002.

[2]. Sharma R, Kapoor B, Verma U. A study of knowledge, attitude, and practices of prescribers regarding adverse drug reaction reporting in a tertiary care teaching hospital in Jammu. Indian J Pharmacol. 2006;38(4):276–9.

[3]. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire-based study to assess knowledge, attitude, and practice of pharmacovigilance among healthcare professionals in a teaching hospital in South India. Perspect Clin Res. 2015;6(1):45–52.

[4]. Bhattacharjee P, Nayak S, Sarkar S, Dey D, Kundu S, Das S. Pharmacovigilance in ophthalmology: an overview. Indian J Ophthalmol. 2019;67(10):1672–9.

[5]. Rathi S, Majumder P, Dutta A. Ocular adverse effects of commonly used systemic drugs. Indian J Pharmacol. 2017;49(5):317–25.

[6]. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: recent developments and future perspectives. Indian J Pharmacol. 2016;48(6):624–8.

[7]. Kiran VS, Aamir M. Drug-induced ocular adverse effects: a comprehensive review. Ther Adv Drug Saf. 2018;9(9):457–75.

[8]. Rehman W, Ahsan A. Attitude and practices of eye care professionals toward pharmacovigilance in Pakistan. Int J Clin Trials. 2020;7(1):1–5.

[9]. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl1):S73–7.

[10]. Hardeep, Bajaj JK, Rakesh K. A survey on the knowledge, attitude, and practice of pharmacovigilance among healthcare professionals in a teaching hospital in Northern India. J Clin Diagn Res. 2013;7(1):97–9.

[11]. Rajurkar K, Dubey S, Gupta PP, John D, Chauhan L. Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India. J Curr Ophthalmol. 2018;30(2):125–9.

[12]. Ramesh PV, Parthasarathi S, John RK. An exploratory study of compliance to anti-glaucoma medications among literate primary glaucoma patients at an urban tertiary eye care center in South India. Indian J Ophthalmol. 2021;69(6):1418–24.

[13]. Khan SA, Goyal C, Chandel N, Rafi M. Knowledge, attitude, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med. 2013;4(1):191–6.

[14]. Desai CK, Iyer G, Panchal J, Shah S, Dikshit RK. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res. 2011;2(4):129–36.

[15]. Kulkarni MD, Baig MS, Chandaliya KC, Doifode SM, Razvi SU, Sindhu NS.

Knowledge, attitude, and practice of pharmacovigilance among prescribers of government medical college and hospital, Aurangabad (Maharashtra). Int J Pharmacol Ther. 2013;3(3):10–8.

[16]. Palaian S, Ibrahim MI, Mishra P. Health professionals' knowledge, attitude, and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9(4):228–35.

[17]. Meher BR, Joshua N, Asha B, Mukherji D. A questionnaire-based study to assess knowledge, attitude, and practice of pharmacovigilance among undergraduate medical students in a tertiary care teaching hospital of South India. Perspect Clin Res. 2015;6(4):217–21.IJBC Pharmacology

[18]. Muraraiah S, Rajarathna K, Sreedhar D, Basavalingu D, Jayanthi CR. A questionnaire study to assess the knowledge, attitude, and practice of pharmacovigilance in a pediatric tertiary care center. J Chem Pharm Res. 2011;3(6):416–22.

[19]. Radhakrishnan R, Sudha V, Dhanaraj SA. An educational intervention to assess knowledge, attitude, practice of pharmacovigilance among healthcare professionals in an Indian tertiary care teaching hospital. Int J Pharm Tech Res. 2011;3(2):678–92.

[20]. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–60.

[21]. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47.

[22]. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2008;65(2):210–6.

[23]. Ganesan S, Vikneswaran G, Reddy KC, Subrahmanyam DK, Adithan C. A survey on knowledge, attitude, and practice of pharmacovigilance towards adverse drug reactions reporting among doctors and nurses